Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders

OBJECTIVE: Conformational change in the last four amino acid of the albumin’s N-terminus is called ischemia-modified albumin (IMA). Metabolic stress factors such as ischemia, hypoxia, acidosis or endothelial injury may cause these conformational modifications. In this study, we hypothesized that the...

Full description

Bibliographic Details
Main Authors: Serhat Tunç, Murat İlhan Atagün, Salim Neşelioğlu, Yelda Yenilmez Bilgin, Hamit Serdar Başbuğ, Özcan Erel
Format: Article
Language:English
Published: AVES 2019-04-01
Series:Psychiatry and Clinical Psychopharmacology
Subjects:
Online Access:http://dx.doi.org/10.1080/24750573.2018.1517466
id doaj-4230c3956c8d4411a6ab471f145a4b43
record_format Article
spelling doaj-4230c3956c8d4411a6ab471f145a4b432021-09-02T15:41:41ZengAVESPsychiatry and Clinical Psychopharmacology2475-05812019-04-0129212312910.1080/24750573.2018.15174661517466Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disordersSerhat Tunç0Murat İlhan Atagün1Salim Neşelioğlu2Yelda Yenilmez Bilgin3Hamit Serdar Başbuğ4Özcan Erel5Kafkas UniversityYildirim Beyazit UniversityYildirim Beyazit UniversityKafkas UniversityKafkas UniversityYildirim Beyazit UniversityOBJECTIVE: Conformational change in the last four amino acid of the albumin’s N-terminus is called ischemia-modified albumin (IMA). Metabolic stress factors such as ischemia, hypoxia, acidosis or endothelial injury may cause these conformational modifications. In this study, we hypothesized that the plasma IMA level changes might help to determine the global metabolic risk in bipolar disorder (BD), unipolar depression (UD), and schizophrenia (SZ). Therefore, it was aimed to investigate metabolic risk factors affecting IMA levels in this study. Modification of the albumin molecule might be a marker of global metabolic risk in schizophrenia and mood disorders. METHOD: The study included 32 patients with BD, 32 patients with UD, 28 patients with SZ and 34 healthy individuals. For determining the IMA levels, standard amounts of cobalt ions were added to the serums, and the quantity of disengaged cobalt ions was measured by colorimetric assay. RESULTS: IMA (F = 3.04, p = 0.032) levels differed between the groups. IMA levels of the BD group were significantly higher than the healthy control group (p = 0.048). White blood cell count in the BD group (p = 0.034) and total oxidant status (TOS) in the SZ group (p < 0.001) were the determinants of IMA levels with linear regression analysis. CONCLUSION: Elevation of IMA levels may indicate a global metabolic risk, and IMA levels are elevated in the BD group in this study. Determinants of IMA levels may indicate the significant metabolic risk in patient groups. Oxidative stress (OS) was the determinant of IMA levels in the SZ, and white blood cell count was the determinant of IMA levels in the BD group. Although the IMA levels were higher in all patient groups, the statistical significance appeared only in the BD group. Elevated IMA level was due to elevated OS in the SZ group, whereas the immunity in the BD group.http://dx.doi.org/10.1080/24750573.2018.1517466ischemia-modified albumindepressionbipolar disorderschizophrenia
collection DOAJ
language English
format Article
sources DOAJ
author Serhat Tunç
Murat İlhan Atagün
Salim Neşelioğlu
Yelda Yenilmez Bilgin
Hamit Serdar Başbuğ
Özcan Erel
spellingShingle Serhat Tunç
Murat İlhan Atagün
Salim Neşelioğlu
Yelda Yenilmez Bilgin
Hamit Serdar Başbuğ
Özcan Erel
Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders
Psychiatry and Clinical Psychopharmacology
ischemia-modified albumin
depression
bipolar disorder
schizophrenia
author_facet Serhat Tunç
Murat İlhan Atagün
Salim Neşelioğlu
Yelda Yenilmez Bilgin
Hamit Serdar Başbuğ
Özcan Erel
author_sort Serhat Tunç
title Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders
title_short Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders
title_full Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders
title_fullStr Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders
title_full_unstemmed Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders
title_sort ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders
publisher AVES
series Psychiatry and Clinical Psychopharmacology
issn 2475-0581
publishDate 2019-04-01
description OBJECTIVE: Conformational change in the last four amino acid of the albumin’s N-terminus is called ischemia-modified albumin (IMA). Metabolic stress factors such as ischemia, hypoxia, acidosis or endothelial injury may cause these conformational modifications. In this study, we hypothesized that the plasma IMA level changes might help to determine the global metabolic risk in bipolar disorder (BD), unipolar depression (UD), and schizophrenia (SZ). Therefore, it was aimed to investigate metabolic risk factors affecting IMA levels in this study. Modification of the albumin molecule might be a marker of global metabolic risk in schizophrenia and mood disorders. METHOD: The study included 32 patients with BD, 32 patients with UD, 28 patients with SZ and 34 healthy individuals. For determining the IMA levels, standard amounts of cobalt ions were added to the serums, and the quantity of disengaged cobalt ions was measured by colorimetric assay. RESULTS: IMA (F = 3.04, p = 0.032) levels differed between the groups. IMA levels of the BD group were significantly higher than the healthy control group (p = 0.048). White blood cell count in the BD group (p = 0.034) and total oxidant status (TOS) in the SZ group (p < 0.001) were the determinants of IMA levels with linear regression analysis. CONCLUSION: Elevation of IMA levels may indicate a global metabolic risk, and IMA levels are elevated in the BD group in this study. Determinants of IMA levels may indicate the significant metabolic risk in patient groups. Oxidative stress (OS) was the determinant of IMA levels in the SZ, and white blood cell count was the determinant of IMA levels in the BD group. Although the IMA levels were higher in all patient groups, the statistical significance appeared only in the BD group. Elevated IMA level was due to elevated OS in the SZ group, whereas the immunity in the BD group.
topic ischemia-modified albumin
depression
bipolar disorder
schizophrenia
url http://dx.doi.org/10.1080/24750573.2018.1517466
work_keys_str_mv AT serhattunc ischemiamodifiedalbuminauniquemarkerofglobalmetabolicriskinschizophreniaandmooddisorders
AT muratilhanatagun ischemiamodifiedalbuminauniquemarkerofglobalmetabolicriskinschizophreniaandmooddisorders
AT salimneselioglu ischemiamodifiedalbuminauniquemarkerofglobalmetabolicriskinschizophreniaandmooddisorders
AT yeldayenilmezbilgin ischemiamodifiedalbuminauniquemarkerofglobalmetabolicriskinschizophreniaandmooddisorders
AT hamitserdarbasbug ischemiamodifiedalbuminauniquemarkerofglobalmetabolicriskinschizophreniaandmooddisorders
AT ozcanerel ischemiamodifiedalbuminauniquemarkerofglobalmetabolicriskinschizophreniaandmooddisorders
_version_ 1721173284586782720